A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer

Sponsor:

NRG

Sponsor Study ID:

NRG HN010

CTO #:

103799

NCT Number:

NCT05408845

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lip, Oral Cavity and Pharynx

Study Objectives:

To determine if trastuzumab emtansine (ado-trastuzumab emtansine [T-DM1]) shows better progression-free survival (PFS) when compared to docetaxel plus trastuzumab (TH) in recurrent and/or metastatic (R/M) HER2-positive salivary gland cancer (SGC) patients who have not previously received HER2 therapy for unresectable or recurrent and/or metastatic disease, as determined by local assessment.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)